ENDPOINTS

Inside the Accolade-Transcarent deal

Feb 20, 2025 - 20:15
 0
Inside the Accolade-Transcarent deal
Read More

Tags:

Previous Article

Antiviral signaling of a type III CRISPR-associated deaminase | Science

Next Article

55 Years Ago: Preps for Apollo 13 and 14, Apollo 12 Crew on World Tour

Related Posts

Biogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet

Biogen downplays capacity for M&A; Roche’s SMA drug is ...

Feb 12, 2025  0

David Schenkein resigns from Agios’ board; Moderna hires Roivant exec as chief marketing officer

David Schenkein resigns from Agios’ board; Moderna hire...

Feb 14, 2025  0

Pfizer CEO says Trump opportunities outweigh risks

Pfizer CEO says Trump opportunities outweigh risks

Feb 19, 2025  0